KRAS and non-small cell lung carcinoma: However, the clinical significance of KRAS as a potential prognostic/predictive biomarker is tempered by contrasting findings, for instance in NSCLC, which most likely reflects the high degree of genetic and molecular heterogeneity among patient tumors (Shepherd et al, 2013).